Mirtazapine · MirtaRett

An Italian open-label study of safety, symptoms and daily life.

Study level

The aim, simply

MirtaRett plans 54 participants in an open-label phase 2 study without placebo. The protocol follows safety, tolerability, sleep, mood, motor function and biomarkers over 10 months.

Criteria: guidance, not eligibility

Protocol criteria say ages 5–39 inclusive. Its summary says 5–40: the team must clarify this difference.

Age follows protocol criteria. The registry summary may show a different bound; the team must confirm it.

What this cannot tell us

A study record describes research, not a guaranteed benefit or treatment access in your country.

Only the trial team can confirm eligibility. Age and country are not enough: the protocol includes other criteria. Status may also vary by study site.

Centre level

Partial list. A registry listing does not confirm a place. Check directly with the site.

Sites not transcribed in this selection. Consult the official record.